Christina Mattina

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, as well as insights into childhood cancer predisposition.

EHA 2026 late-breaking data featured phase 3 trials in CLL, AML, multiple myeloma, and myelofibrosis, as well as early CAR T data in B-cell lymphoma and ITP.

As drug research globalizes, regulators and trial designers must collaborate across regions to bring new treatments to patients.

Experts sparred over the feasibility and appropriateness of using minimal residual disease (MRD) to determine the duration of first-line CLL treatment.

Final results of the CLL14 study reveal the efficacy of 1-year venetoclax-obinutuzumab therapy for chronic lymphocytic leukemia.

Longer patient survival times require a shift toward earlier surrogate end points, with measurable residual disease (MRD) providing robust evidence of its utility for accelerating access to myeloma treatment.

A thriving gut microbiome is associated with better clinical outcomes after CAR T-cell therapy for lymphoma and myeloma.

The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery.

Participants exposed critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure with preserved ejection fraction and charted a path forward.

Clinicians discussed the fragmented state of obesity care, emphasizing the need for coordinated models, earlier intervention, and improved access to effective therapies.

A multidisciplinary roundtable exposed deep inequities in vitiligo care—from payer misclassification to access barriers—while charting a more ambitious treatment future.

Amid disagreements between the FDA and White House on drug approvals, vapes, and mifepristone, the tenure of Marty Makary, MD, as commissioner has come to an end.

The approval marks the first treatment for the rare disease marked by rapid and sustained weight gain caused by hypothalamic injury or dysfunction.

Accountable care experts say the future of value in Medicare will rely on scaling up innovation, emphasizing downstream prevention, and staying alert to waste.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Highlights from the 2025 Muscular Dystrophy Association (MDA) Conference include clinical updates, expert insights, and breaking trial findings.

This year’s most-read articles on CLL highlighted research and insights on personalized therapy, long-term remission, and next-generation cell treatments.

Readers of PHEO this year found value in research, conference coverage, and insights that touched on health outcomes and care quality.

Readers of AJMC gravitated to articles on technology, policy, and clinical workflows, reflecting the pursuit of improved quality and responsible spending.

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from treatment of individual diseases to team-based, population-focused care.

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies.

In 2025, each issue of Population Health, Equity & Outcomes has featured a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with B. Joy Snider, MD, PhD, professor of neurology at Washington University in St Louis.

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.

Diet and wellness impact multiple sclerosis management, enhancing quality of life and reducing fatigue through lifestyle changes and holistic approaches.

Explore how the Veteran Affairs (VA) MS Centers of Excellence enhance veteran care through a hub-and-spoke model, telehealth, and groundbreaking research.

Nurse practitioners play an essential role in diagnosing, treating, and supporting individuals living with Alzheimer disease.

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression.

To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The November issue features a conversation with Laurie C. Zephyrin, MD, MPH, MBA, senior vice president for achieving equitable outcomes at the Commonwealth Fund. This interview has been edited for length and clarity.

Darla Chapman, DNP, ARNP, University of Washington, speaks on the evolution of Alzheimer diagnosis, emphasizing early detection and innovative biomarkers.